Lifeboat Foundation

The oral and skin care brand has already undertaken two other experiments on the space station.

Colgate-Palmolive Company and NASA have entered into a partnership to explore innovative solutions to advance oral health, personal care and skin health for astronauts and even populations on earth, according to a press release by the self-care company published on Wednesday.

The deal will see former astronaut Dr. Cady Coleman join the team as an advisor for the experiments conducted.

Continue reading “NASA partners with US company to send astronauts grooming supplies for use and testing” »

The study brings much hope to patients with brain and spinal cord cancers.

A small pilot trial involving patients with lymphoma of the brain and/or spinal cord has shown that CAR-T-cell therapy known as axicabtagene ciloleucel (axi-cel) can be a viable treatment option for patients who often have little hope, according to a press release by Dana-Farber Cancer Institute investigators published on Sunday. “For many patients with lymphoma of the central nervous system, there aren’t great treatment options,” said Dana-Farber’s Caron Jacobson, MD, MMSc, who led the trial.

Our early results suggest that expanding the applicability of CAR-T cells to this indication could improve patient outcomes.

Continue reading “Pilot trial sees tumors shrink or disappear in 78% of patients” »

Today, the University of Colorado Cancer Center released new research that showcases chemotherapy treatment before and after surgery for pancreatic cancer as the most effective combination for patients.

The study findings were published in JAMA Oncology and led by Marco Del Chiaro, MD, division chief of surgical oncology in the University of Colorado Department of Surgery and visiting researcher Toshitaka Sugawara, MD, Ph.D.

“It’s critical to have large scale data that doctors can use to make decisions about chemotherapy plans for patients who qualify for pancreatic cancer surgery,” said author Marco Del Chiaro, MD, division chief of surgical oncology at the CU Cancer Center on the University of Colorado Anschutz Medical Campus.

The fight against Alzheimer’s disease has been a tough one, but we are making progress. Not only have scientists created tech that can detect Alzheimer’s in a single brain scan, but some research has also shown that repurposable drugs could help find a cure.

https://www.youtube.com/watch?v=vpOliRELIyQ

While Elon Musk’s Tesla has been making waves in the global auto industry, China has also become the center of action in the EV space! One company in China has recorded.

A breakthrough in battery technology so huge that even Musk is impressed! Which.

Continue reading “China JUST REVEALED Battery Breakthrough That Charges Faster Than Gasoline!” »

One thing the Star Trek franchise has no shortage of across its many iterations and separate series storylines is the array of world-ending technological horrors always facing the constantly hounded Federation, and The Original Series started it all with this planet-destroying weapon of unknown origin which appeared in the episode of the same name.

Though the crew never quite figures out exactly what it is or where its origins lay, Kirk theorized it was constructed as a bluff to deter one side of an undetermined galactic war, reflecting the Mutual Assured Destruction fears of the time between the U.S. and Russia. It’s pretty much Star Trek’s famous answer to the Death Star, albeit ten years before Episode 4 would make its debut.

Hunting for lightweight dark matter particles requires detectors with much lower signal thresholds than traditional experiments. This requirement has prompted novel detection techniques, including probing the faint interactions that occur between sub-MeV particles and electrons. In a 180-hour-long experiment, Yonit Hochberg of the Hebrew University of Jerusalem and her colleagues demonstrate a device that distinguishes hypothetical sub-MeV dark matter from background noise with record sensitivity [1]. Their experiment places the strongest constraints yet on interactions between lightweight dark matter and regular matter.

Hochberg and her colleagues etched an array of nanowires in a 7-nm-thick tungsten-silicide film to produce a superconducting nanowire single-photon detector, a sensor that is sensitive to extremely small energy inputs. When energy above some threshold is deposited on a superconducting nanowire, the wire briefly becomes a regular conductor, resulting in a voltage pulse.

The team circulated a fixed current through their device and sealed it in a light-tight box for 180 hours. They counted four voltage pulses, each corresponding to a deposited energy of at least 0.73 eV. Absent any other detectable energy source, these dark counts could be attributed to cosmic-ray-generated muons or high-energy particles excited by radioactive decay.

A pair of microspheres can convert microwave signals over a wide frequency range into optical signals, which will be essential for future quantum technologies.

Future quantum communication systems will likely use microwaves to transfer information into and out of storage and processing devices but will use lasers to carry information from point to point within an extended network. Now researchers have demonstrated an improved method for converting microwaves to visible light signals by exploiting the way that electromagnetic waves can set up vibrations within microspheres [1]. Two microspheres in contact—one sensitive to microwaves and the other sensitive to optical signals—serve as the core of the converter. The work should give researchers a wider range of technological options as they develop advanced communications and computing networks.

Researchers are pursuing a variety of ways to store quantum information, or “qubits,” in microscopic, typically superconducting, structures. One common feature of such technologies is that reading or writing information relies on interactions with microwaves rather than on higher-frequency visible or infrared light from lasers. But lasers offer the best way to move information around, so extended networks of such devices will need ways to convert signals from one form to the other.

A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73% of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.

The therapy, known as a bispecific antibody, binds to both T cells and multiple myeloma cells and directs the T cells— white blood cells that can be enlisted to fight off diseases—to kill multiple myeloma cells. The researchers described this strategy as “bringing your army right to the enemy.”

The success of the off-the-shelf immunotherapy, called talquetamab, was even seen in patients whose cancer was resistant to all approved multiple myeloma therapies. It uses a different target than other approved therapies: a receptor expressed on the surface of cancer cells known as GPRC5D.